Two Drug Products Discontinued
March 18, 2019 – Two manufactures, CSL Behring and Grifols USA, have announced the withdrawal of drug products from the market due to business considerations.
CSL Behring has ceased shipments of Monoclate-P® (antihemophilic factor VIII [human]). Used to treat hemophilia A, the product has been losing sales to newer treatments created through recombinant technology. Unlike recombinant products, Monoclate-P is derived from human blood plasma.
Grifols announced a market withdrawal of Flebogamma® DIF (immune globulin intravenous [human]) effective April 1, 2019. The product is used to treat primary immunodeficiencies, including primary immune thrombocytopenia (ITP) and severe combined immunodeficiency. It is available in two strengths. The 10% strength is also used to treat idiopathic thrombocytopenic purpura (ITP). Grifols is working to switch all patients who use Flebogamma to Gamunex®-C (immune globulin injection [human], 10% caprylate/chromatography purified) for continued treatment.